ketendoКлиническая и экспериментальная тиреоидологияClinical and experimental thyroidology1995-54722310-3787Endocrinology Research Centre10.14341/ket12839ketendo-12839Research ArticleКлинические рекомендацииClinical GuidelinesНовые клинические рекомендации: «Тиреотоксикоз с диффузным зобом (болезнь Грейвса), узловым/многоузловым зобом»New clinical guidelines: "Thyrotoxicosis associated with diffuse goiter (Graves’ disease), nodular and multinodular goiterhttps://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaE. A.

Трошина Екатерина Анатольевна, д.м.н., член-корр. РАН, профессор

Москва

Ekaterina A. Troshina, MD, Corresponding Member of the Russian Academy of Sciences, Dr. Sci. (Medicine), Professor

Moscow

troshina@inbox.ruhttps://orcid.org/0000-0002-8538-5354СвириденкоН. Ю.SviridenkoN. Yu.

Свириденко Наталья Юрьевна, д.м.н., профессор

Москва

Natalya Yu. Sviridenko, MD, Dr. Sci. (Medicine), Professor

Moscow

natsvir@inbox.ruhttps://orcid.org/0000-0001-6388-1544ПлатоноваН. М.PlatonovaN. M.

Платонова Надежда Михайловна, д.м.н.

Москва

Nadezhda M. Platonova, MD, Dr. Sci. (Medicine)

Moscow

doc-platonova@inbox.ruhttps://orcid.org/0000-0002-9954-7641БеловаловаИ. М.BelovalovaI. M.

Беловалова Ирина Михайловна, к.м.н.

Москва

Irina M. Belovalova, MD, Cand. Sci. (Medicine)

Moscow

belovalova.irina@endocrincentr.ruhttps://orcid.org/0000-0003-3785-0335ШереметаМ. С.SheremetaM. S.

Шеремета Марина Сергеевна, д.м.н. 

Москва

Marina S. Sheremeta, MD, Dr. Sci. (Medicine)

Moscow

marina888@yandex.ruhttps://orcid.org/0000-0001-5910-6502БессмертнаяЕ. Г.BessmertnayaE. G.

Бессмертная Елена Григорьевна, к.м.н.

Москва

Elena G. Bessmertnaya, MD, Cand. Sci. (Medicine)

Moscow

bessmertnaya.eg@gmail.comhttps://orcid.org/0000-0002-9296-4346ЯновскаяЕ. А.YanovskayaE. A.

Яновская Елена Александровна, к.м.н.

Ярославль

Elena A. Yanovskaya, MD, Cand. Sci. (Medicine)

Yaroslavl 

lenayan2005@rambler.ruhttps://orcid.org/0000-0001-7581-1543АлександровЮ. К.AleksandrovYu. K.

Александров Юрий Константинович, д.м.н.

Ярославль

Yuri K. Aleksandrov, MD, Dr. Sci. (Medicine) Professor

Yaroslavl

yka2000@mail.ruhttps://orcid.org/0000-0002-7624-7953ЯсюченяВ. С.YasucheniaV. S.

Ясюченя Валентина Сергеевна

Москва

Valentina S. Yasuchenia, MD

Moscow

loveissiberia@gmail.comhttps://orcid.org/0009-0009-2521-2978СырцоваЕ. И.SyrtsovaE. I.

Сырцова Екатерина Игоревна

117292,

Москва, ул. Дм. Ульянова, д. 11

Ekaterina I. Syrtsova, MD

11 Dm.Ulyanova street, 117292, Moscow

syrcovae@mail.ruНациональный медицинский исследовательский центр эндокринологии им. академика И.И. ДедоваРоссияEndocrinology Research CenterRussian FederationЯрославская областная клиническая больницаРоссияYaroslavl Regional Clinical HospitalRussian FederationРЖД-МедицинаРоссияRZD-MedicineRussian Federation2025160620262133255Copyright © Трошина Е.А., Свириденко Н.Ю., Платонова Н.М., Беловалова И.М., Шеремета М.С., Бессмертная Е.Г., Яновская Е.А., Александров Ю.К., Ясюченя В.С., Сырцова Е.И., 20262026Трошина Е.А., Свириденко Н.Ю., Платонова Н.М., Беловалова И.М., Шеремета М.С., Бессмертная Е.Г., Яновская Е.А., Александров Ю.К., Ясюченя В.С., Сырцова Е.И.Troshina E.A., Sviridenko N.Y., Platonova N.M., Belovalova I.M., Sheremeta M.S., Bessmertnaya E.G., Yanovskaya E.A., Aleksandrov Y.K., Yasuchenia V.S., Syrtsova E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cet-endojournals.ru/jour/article/view/12839

В июне 2025 года в Российской Федерации вышли обновленные клинические рекомендации по диагностике и лечению тиреотоксикоза, разработанные на основе актуальных научных данных, реалий клинической практики и международных стандартов.

Особое внимание уделено изменениям в подходах к ведению пациентов с тиреотоксикозом, вызванным диффузным токсическим зобом (болезнью Грейвса), а также узловым и многоузловым токсическим зобом. В работе выделены наиболее существенные и концептуальные сдвиги — как в диагностических алгоритмах, так и в стратегиях терапии, включая приоритеты медикаментозного лечения, критерии назначения хирургического вмешательства и радиойодтерапии.

Сравнительный анализ позволяет проследить эволюцию клинического мышления и процесс стандартизации оказания помощи пациентам с тиреотоксикозом в современной эндокринологии.

Цель данного обзора — повысить информированность специалистов и способствовать формированию критически осмысленного, взвешенного и персонализированного подхода к применению клинических рекомендаций в практике диагностики и лечения тиреотоксикоза.

In June 2025, updated clinical guidelines for the diagnosis and management of thyrotoxicosis were released in the Russian Federation, developed on the basis of current scientific evidence, real-world clinical practice, and international standards. The document highlights the most significant and conceptual shifts — both in diagnostic algorithms and therapeutic strategies — including priorities in pharmacological treatment, and criteria for surgical intervention and radioiodine therapy. A comparative analysis reveals the evolution of clinical reasoning and the ongoing standardization of care for patients with thyrotoxicosis in contemporary endocrinology.

The aim of this review is to enhance clinicians’ awareness and promote a critically informed, balanced, and personalized approach to implementing these clinical guidelines in the diagnosis and treatment of thyrotoxicosis.

Болезнь Грейвсадиффузный токсический зобмногоузловой токсический зобтиреотоксический кризузловой токсический зобщитовидная железаэндокринная офтальмопатияGraves’ diseasediffuse toxic goitertoxic multinodular goiterthyroid storm (thyrotoxic crisis)toxic nodular goiterthyroid eye disease (TED)Graves' ophthalmopathythyroid-associated ophthalmopathy (TAO)ReferencesФадеев В.В., Абрамова Н.А., Прокофьев С.А., Гитель Е.П., Мельниченко Г.А, Дедов И.И. Антитела к рецептору ТТГ в дифференциальной диагностике токсического зоба. // Проблемы эндокринологии. — 2005. — Т.51. — №4. — С.10–18. doi: https://doi.org/10.14341/probl200551410-18Fadeyev VV, Abramova NA, Prokofiev SA, Gitel EP, Mel'nichenko GA, Dedov II. Thyroid-stimulating hormone receptor antibodies in the differential diagnosis of toxic goiter. Problems of Endocrinology. 2005;51(4):10-18. (In Russ.)] doi: https://doi.org/10.14341/probl200551410-18Свириденко Н.Ю., Лихванцева В.Г., Беловалова И.М., Шеремета М.С., Табеева К.И. Антитела к рецептору ТТГ как предикторы тяжести и исходов эндокринной офтальмопатии у пациентов с болезнью Грейвса. // Проблемы эндокринологии. — 2011. — №2. — С.23-26. doi: https://doi.org/10.14341/probl201157223-26Sviridenko NI, Likhvantseva VG, Belovalova IM, Sheremeta MS, Tabeeva KI. Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves' disease. Problems of Endocrinology. 2011;57(2):23-26 (In Russ.)]. doi: https://doi.org/10.14341/probl201157223-26Rapoport B, McLachlan SM. TSH receptor cleavage into subunits and shedding of the Asubunit; a molecular and clinical perspective. Endocr Rev. 2016; 37:114–134. doi: https://doi.org/10.1210/er.2015-1098Rapoport B, McLachlan SM. TSH receptor cleavage into subunits and shedding of the Asubunit; a molecular and clinical perspective. Endocr Rev. 2016; 37:114–134. doi: https://doi.org/10.1210/er.2015-1098Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res. Clin Endocrinol Metab. 2012; 26(3):291–302. doi: https://doi.org/10.1016/j.beem.2011.10.002Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res. Clin Endocrinol Metab. 2012; 26(3):291–302. doi: https://doi.org/10.1016/j.beem.2011.10.002Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–934. doi: https://doi.org/10.1210/jcem.86.2.7242Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–934. doi: https://doi.org/10.1210/jcem.86.2.7242Inaba H, De Groot LJ, Akamizu T: Thyrotropin receptor epitope and human leukocyte antigen in Graves’ disease. Front Endocrinol. 2016;7:120. doi: https://doi.org/10.3389/fendo.2016.00120Inaba H, De Groot LJ, Akamizu T: Thyrotropin receptor epitope and human leukocyte antigen in Graves’ disease. Front Endocrinol. 2016;7:120. doi: https://doi.org/10.3389/fendo.2016.00120Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82–90. doi: https://doi.org/10.1016/j.jaut.2015.07.009Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82–90. doi: https://doi.org/10.1016/j.jaut.2015.07.009Brix TH, Hansen PS, Kyvik KO, Hegedus L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160:661–666. doi: https://doi.org/10.1001/archinte.160.5.661Brix TH, Hansen PS, Kyvik KO, Hegedus L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160:661–666. doi: https://doi.org/10.1001/archinte.160.5.661Manji N, Carr-Smith JD, Boelaert K, et al. Influences of age, gender, smoking and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006;91(12):4873-4880. doi: https://doi.org/10.1210/jc.2006-1402Manji N, Carr-Smith JD, Boelaert K, et al. Influences of age, gender, smoking and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006;91(12):4873-4880. doi: https://doi.org/10.1210/jc.2006-1402Свириденко Н.Ю. Функциональная автономия при эндемическом зобе. Проблемы эндокринологии. 2005;1:40–42. doi: https://doi.org/10.14341/probl200551140-41Свириденко Н.Ю. Функциональная автономия при эндемическом зобе. Проблемы эндокринологии. 2005;1:40–42. doi: https://doi.org/10.14341/probl200551140-41Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10): 1343–1421. doi: https://doi.org/10.1089/thy.2016.0229Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10): 1343–1421. doi: https://doi.org/10.1089/thy.2016.0229Российская ассоциация эндокринологов. Национальные рекомендации: Тиреотоксикоз с диффузным зобом (диффузный токсический зоб, болезнь Грейвса–Базедова), узловым/ многоузловым зобом. М.; 2014.Rossijskaya associaciya endokrinologov. Nacional'nye rekomendacii: Tireotoksikoz s diffuznym zobom (diffuznyj toksicheskij zob, bolezn' Grejvsa–Bazedova), uzlovym/mnogouzlovym zobom. M.; 2014. (In Russ.)]Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 2011; 17(3): 456–520. doi: https://doi.org/10.4158/ep.17.3.456Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 2011; 17(3): 456–520. doi: https://doi.org/10.4158/ep.17.3.456Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005. Clin Endocrinol. 2013;78: 768–776. doi: https://doi.org/10.1111/cen.12060Nystrom HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005. Clin Endocrinol. 2013;78: 768–776. doi: https://doi.org/10.1111/cen.12060McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ ethnicity in US military personnel. JAMA. 2014;311:1563–1565. doi: https://doi.org/10.1001/jama.2013.285606McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ ethnicity in US military personnel. JAMA. 2014;311:1563–1565. doi: https://doi.org/10.1001/jama.2013.285606Свириденко Н.Ю. Тиреотоксикоз. Национальное руководство «Общая врачебная практика» / под ред. И.Н. Денисова, О.М. Лесняк. М.: ГЭОТАР-Медиа; 2013. С. 677–689. [Sviridenko NYu. Tireotoksikoz. Nacional'noe rukovodstvo «Obshchaya vrachebnaya praktika» / pod redakciej red. I.N. Denisova, O.M. Lesnyak. M.: GEOTAR-Media; 2013. S. 677–689 (In Russ.)]Sviridenko NYu. Tireotoksikoz. Nacional'noe rukovodstvo «Obshchaya vrachebnaya praktika» / pod redakciej red. I.N. Denisova, O.M. Lesnyak. M.: GEOTAR-Media; 2013. S. 677–689 (In Russ.)]van de Ven AC, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeney LA, Smit JW, Hermus AR, den Heijer M. Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol. 2014;171(2):183–191. doi: https://doi.org/10.1530/EJE-13-1070van de Ven AC, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeney LA, Smit JW, Hermus AR, den Heijer M. Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol. 2014;171(2):183–191. doi: https://doi.org/10.1530/EJE-13-1070Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431–443. doi: https://doi.org/10.1038/nrendo.2010.105Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431–443. doi: https://doi.org/10.1038/nrendo.2010.105Дедов И.И., Калашников В.Ю., Терехин С.А., Головенко Е.Н., Свириденко Н.Ю., Мелкозеров К.В., Парфененкова А.А., Копылов Ф.Ю., Грибанова А.В. Фатальный спазм коронарной артерии у пациента с тиреотоксикозом. // Кардиология. — 2012. — Т.52. — №11. — С.92–96Dedov II, Kalashnikov VYu, Terekhin SA, Golovenko EN, Sviridenko NYu, Melkozerov KV, Parfenenkova AA, Kopylov FYu, Gribanova AV. Fatal'nyj spazm koronarnoj arterii u pacienta s tireotoksikozom. Kardiologiya. 2012;52(11):92–96 (In Russ.)]Свириденко Н.Ю., Тугеева Э.Ф., Арипов М.А., Бузиашвили Ю.И. Функциональный резерв сердца и показатели левого желудочка у больных диффузным токсическим зобом после медикаментозного восстановления эутиреоза тиамазолом. // Проблемы эндокринологии. — 2009. — Т.55. — №3. — С.21–24. doi: https://doi.org/10.14341/probl200955321-24Sviridenko NY, Tugeeva EF, Aripov MA, Buziashvili YuI. Cardiac functional reserve and left ventricular parameters in patients with diffuse toxic goiter after drug correction of euthyroidism with thiamazol. Problems of Endocrinology. 2009;55(3):21-24. (In Russ.)] doi: https://doi.org/10.14341/probl200955321-24Свириденко Н.Ю., Беловалова И.М., Шеремета М.С., Табеева К.И., Ремизов О.В. Болезнь Грейвса и эндокринная офтальмопатия / Под редакцией академика РАН И.И. Дедова и академика РАН Г.А. Мельниченко. М.: МАИ-ПРИНТ; 2012. 143 сSviridenko NYu, Belovalova IM, Sheremeta MS, Tabeeva KI, Remizov OV. Bolezn' Grejvsa i endokrinnaya oftal'mopatiya / Pod redakciej akademika RAN I.I. Dedova i akademika RAN G.A. Mel'nichenko. M.: MAI-PRINT; 2012. 143 s (In Russ.)]Fadeyev V. Clinical Aspects of Thyroid Disorders in the Elderly Thyroid international. 2007;3:4–15Fadeyev V. Clinical Aspects of Thyroid Disorders in the Elderly Thyroid international. 2007;3:4–15Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, Bandinelli S, Guralnik JM, Valenti G, Ferrucci L. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. J Am Geriatr Soc. 2013; 61:868–874Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, Bandinelli S, Guralnik JM, Valenti G, Ferrucci L. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. J Am Geriatr Soc. 2013; 61:868–874Sohn SY, Lee E, Lee MK, Lee JH. The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies. Endocrinol Metab (Seoul). 2020;35(4):786–800. doi: https://doi.org/10.3803/EnM.2020.728Sohn SY, Lee E, Lee MK, Lee JH. The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies. Endocrinol Metab (Seoul). 2020;35(4):786–800. doi: https://doi.org/10.3803/EnM.2020.728Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–2065. doi: https://doi.org/10.1001/jama.2015.5161Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–2065. doi: https://doi.org/10.1001/jama.2015.5161Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724–734. doi: https://doi.org/10.1038/nrendo.2013.193Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724–734. doi: https://doi.org/10.1038/nrendo.2013.193Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med. 2017;376(2): 184. doi: https://doi.org/10.1056/NEJMc1614624Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med. 2017;376(2): 184. doi: https://doi.org/10.1056/NEJMc1614624Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107–113. doi: https://doi.org/10.1016/j.autrev.2012.07.003Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107–113. doi: https://doi.org/10.1016/j.autrev.2012.07.003Kahaly GJ, Diana T. TSH receptor antibody functionality and nomenclature. Front Endocrinol. 2017;8:28. doi: https://doi.org/10.3389/fendo.2017.00028Kahaly GJ, Diana T. TSH receptor antibody functionality and nomenclature. Front Endocrinol. 2017;8:28. doi: https://doi.org/10.3389/fendo.2017.00028Kiefer FW, Klebermass-Schrehof K, Steiner M, Worda C, Kasprian G, Diana T, Kahaly GJ, Gessl A. Fetal/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto thyroiditis. J Clin Endocrinol Metab. 2017;102(1):6–9. doi: https://doi.org/10.1210/jc.2016-2999Kiefer FW, Klebermass-Schrehof K, Steiner M, Worda C, Kasprian G, Diana T, Kahaly GJ, Gessl A. Fetal/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto thyroiditis. J Clin Endocrinol Metab. 2017;102(1):6–9. doi: https://doi.org/10.1210/jc.2016-2999Goichot B, Bouee S, Castello-Bridoux C, Caron P: Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J. 2017;6(3):152–159. doi: https://doi.org/10.1159/000453260Goichot B, Bouee S, Castello-Bridoux C, Caron P: Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J. 2017;6(3):152–159. doi: https://doi.org/10.1159/000453260Hegedus L. Thyroid ultrasound. Endocrinol Metab Clin North Am. 2001;30(2):339–360. doi: https://doi.org/10.1016/s0889-8529(05)70190-0Hegedus L. Thyroid ultrasound. Endocrinol Metab Clin North Am. 2001;30(2):339–360. doi: https://doi.org/10.1016/s0889-8529(05)70190-0Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid. 2007;17(3):223–228. doi: https://doi.org/10.1089/thy.2006.0104Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid. 2007;17(3):223–228. doi: https://doi.org/10.1089/thy.2006.0104Ralls PW, Mayekawa DS, Lee KP, Colletti PM, Radin DR, Boswell WD, Halls JM. Color-flow Doppler sonography in Graves disease: thyroid inferno. AJR Am J Roentgenol. 1988;150(4):781–784. doi: https://doi.org/10.2214/ajr.150.4.781Ralls PW, Mayekawa DS, Lee KP, Colletti PM, Radin DR, Boswell WD, Halls JM. Color-flow Doppler sonography in Graves disease: thyroid inferno. AJR Am J Roentgenol. 1988;150(4):781–784. doi: https://doi.org/10.2214/ajr.150.4.781Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab. 2008;4(2):70–71. doi: https://doi.org/10.1038/ncpendmet0692Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab. 2008;4(2):70–71. doi: https://doi.org/10.1038/ncpendmet0692Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L., Poppe K., Pearce S.H. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal. 2018; 7(4): 167-186. doi: https://doi.org/10.1159/000490384Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L., Poppe K., Pearce S.H. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal. 2018; 7(4): 167-186. doi: https://doi.org/10.1159/000490384Wang J, Zhang R Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol. 2017;90(1071):20160836. doi: https://doi.org/10.1259/bjr.20160836Wang J, Zhang R Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol. 2017;90(1071):20160836. doi: https://doi.org/10.1259/bjr.20160836Свириденко Н.Ю., Платонова Н.М., Молашенко Н.В., Голицин С.П., Бакалов С.А., Сердюк С.Е. Эндокринные аспекты применения амиодарона в клинической практике. (Алгоритм наблюдения и лечения функциональных расстройств щитовидной железы). // Российский кардиологический журнал. — 2012. — Т.2. — №94. — С.63–71.Sviridenko NYu, Platonova NM, Molashenko NV, Golitsyn SP, Bakalov SA, Serdyuk SE. Endocrine Aspects Of Amiodarone Therapy In Clinical Practice (Follow-Up And Treatment Algorithm For Patients With Thyroid Dysfunction). Russian Journal of Cardiology. 2012;(2):63-71. (In Russ.)]Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, Xu Q, Dong MJ. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid. 2016(5);26:627–633. doi: https://doi.org/10.1089/thy.2015.0439Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, Xu Q, Dong MJ. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid. 2016(5);26:627–633. doi: https://doi.org/10.1089/thy.2015.0439Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol. 2004;61(5):589–594. doi: https://doi.org/10.1111/j.1365-2265.2004.02135.xPearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol. 2004;61(5):589–594. doi: https://doi.org/10.1111/j.1365-2265.2004.02135.xСвириденко Н.Ю., Колода Д.Е. Антитиреоидные средства. В кн.: Рациональная фармакотерапия заболеваний эндокринной системы и нарушения обмена веществ: Руководство для практикующих врачей / Под общ. ред. И.И. Дедова, Г.А. Мельниченко. М.: Литтерра, 2013. C. 85–90.Sviridenko NYu, Koloda DE. Antitireoidnye sredstva. V kn.: Racional'naya farmakoterapiya zabolevanij endokrinnoj sistemy i narusheniya obmena veshchestv: Rukovodstvo dlya praktikuyushchih vrachej / Pod obshch. red. I.I. Dedova, G.A. Mel'nichenko. M.: Litterra, 2013. C. 85–90. (In Russ.)]Laurberg P, Berman DC, Andersen S, Bulow Pedersen I: Sustained control of Graves’ hyperthyroidism during longterm low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid. 2011;21(9):951–956. doi: https://doi.org/10.1089/thy.2011.0039Laurberg P, Berman DC, Andersen S, Bulow Pedersen I: Sustained control of Graves’ hyperthyroidism during longterm low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid. 2011;21(9):951–956. doi: https://doi.org/10.1089/thy.2011.0039Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474–3481. doi: https://doi.org/10.1210/jc.2003-030185Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474–3481. doi: https://doi.org/10.1210/jc.2003-030185Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95(5):2227–2233. doi: https://doi.org/10.1210/jc.2009-2752Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95(5):2227–2233. doi: https://doi.org/10.1210/jc.2009-2752Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Montori VM. Antithyroid drugs — the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26(8):1144–1145. doi: https://doi.org/10.1089/thy.2016.0222Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, Montori VM. Antithyroid drugs — the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26(8):1144–1145. doi: https://doi.org/10.1089/thy.2016.0222Hallberg P, Eriksson N, Ibanez L, Bondon-Guitton E, Kreutz R, Carva-jal A, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016;4:507–16Hallberg P, Eriksson N, Ibanez L, Bondon-Guitton E, Kreutz R, Carva-jal A, et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016;4:507–16Cooper DS. Antithyroid drugs. N Engl J Med. 2005;3:352(9):905–917. doi: https://doi.org/10.1056/NEJMra042972Cooper DS. Antithyroid drugs. N Engl J Med. 2005;3:352(9):905–917. doi: https://doi.org/10.1056/NEJMra042972Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a populationbased cohort study. Br J Clin Pharmacol. 2014;78(3):619–629. doi: https://doi.org/10.1111/bcp.12336Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a populationbased cohort study. Br J Clin Pharmacol. 2014;78(3):619–629. doi: https://doi.org/10.1111/bcp.12336Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for reating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:CD003420. doi: https://doi.org/10.1002/14651858.CD003420.pub4.Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for reating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:CD003420. doi: https://doi.org/10.1002/14651858.CD003420.pub4.Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, Kaise K, Higashi K, Tanabe M, Shimazu S, Usui T, Shimatsu A, Naruse M. BBGD Study Group. Shortterm effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012;51(17):2285–2290. doi: https://doi.org/10.2169/internalmedicine.51.7302Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, Kaise K, Higashi K, Tanabe M, Shimazu S, Usui T, Shimatsu A, Naruse M. BBGD Study Group. Shortterm effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012;51(17):2285–2290. doi: https://doi.org/10.2169/internalmedicine.51.7302Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, Schuetz P. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:87–97Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, Schuetz P. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:87–97Diana T, Krause J, Olivo PD, Konig J, Kanitz M, Decallonne B, Kahaly GJ: Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol. 2017;189:304–309Diana T, Krause J, Olivo PD, Konig J, Kanitz M, Decallonne B, Kahaly GJ: Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol. 2017;189:304–309Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS: Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid. 2015;25:12821290Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS: Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid. 2015;25:12821290Donovan PJ, McLeod DS, Little R, Gordon L. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’disease. Eur J Endocrinol. 2016;175(6):595–603. doi: https://doi.org/10.1530/EJE-16-0527Donovan PJ, McLeod DS, Little R, Gordon L. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’disease. Eur J Endocrinol. 2016;175(6):595–603. doi: https://doi.org/10.1530/EJE-16-0527Фомин Д.К., Свириденко Н.Ю., Румянцев П.О. Терапия радиоактивным йодом. В кн.: Национальное руководство: Эндокринология / Под ред. И.И. Дедова, Г.А. Мельниченко. М.: ГЭОТАР-Медиа, 2016. С. 381-390. [Fomin DK, Sviridenko NYu, Rumyancev PO. Terapiya radioaktivnym jodom. V kn.: Nacional'noe rukovodstvo: Endokrinologiya / Pod red. I.I. Dedova, G.A. Mel'nichenko. M.: GEOTAR-Media, 2016. S. 381-390. (In Russ.)]Fomin DK, Sviridenko NYu, Rumyancev PO. Terapiya radioaktivnym jodom. V kn.: Nacional'noe rukovodstvo: Endokrinologiya / Pod red. I.I. Dedova, G.A. Mel'nichenko. M.: GEOTAR-Media, 2016. S. 381-390. (In Russ.)]ICRP, 2000. Pregnancy and Medical Radiation. ICRP Publication 84. Ann. ICRP 30 (1).ICRP, 2000. Pregnancy and Medical Radiation. ICRP Publication 84. Ann. ICRP 30 (1).American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335-46. doi: https://doi.org/10.1089/thy.2010.0403American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335-46. doi: https://doi.org/10.1089/thy.2010.0403Berg GE, Nyström EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, Norén AH, Westphal OG. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998;39(2):357–361Berg GE, Nyström EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, Norén AH, Westphal OG. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998;39(2):357–361Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf ). 2008;69(3):479–90. doi: https://doi.org/10.1111/j.1365-2265.2008.03222.xSawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf ). 2008;69(3):479–90. doi: https://doi.org/10.1111/j.1365-2265.2008.03222.xSilberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-51. doi: https://doi.org/10.2967/jnumed.112.105148Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-51. doi: https://doi.org/10.2967/jnumed.112.105148Ross D.S. (2015) Radioiodine Treatment in Patients with Graves’ Disease. In: Bahn R. (eds) Graves' Disease. Springer, New York, NY. doi: https://doi.org/10.1007/978-1-4939-2534-6_7Ross D.S. (2015) Radioiodine Treatment in Patients with Graves’ Disease. In: Bahn R. (eds) Graves' Disease. Springer, New York, NY. doi: https://doi.org/10.1007/978-1-4939-2534-6_7Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013;23(5):620-625. doi: https://doi.org/10.1089/thy.2012.0258Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013;23(5):620-625. doi: https://doi.org/10.1089/thy.2012.0258Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P, Hansen JM. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Intern Med. 1995;238(6):491–497. doi: https://doi.org/10.1111/j.1365-2796.1995.tb01230.xNygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P, Hansen JM. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Intern Med. 1995;238(6):491–497. doi: https://doi.org/10.1111/j.1365-2796.1995.tb01230.xSridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med. 1984;16:311(7):426–32. doi: https://doi.org/10.1056/NEJM198408163110702Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med. 1984;16:311(7):426–32. doi: https://doi.org/10.1056/NEJM198408163110702Фадеев В.В., Дроздовский Б.Я., Гусева Т.Н., Гарбузов П.И., Бузиашвили И.И., Мельниченко Г.А. Отдаленные результаты лечения токсического зоба радиоактивным 131I. // Проблемы эндокринологии. — 2005. — Т.51. — №1. — С.3–9. doi: https://doi.org/10.14341/probl20055113-9Fadeyev VV, Drozdovsky ВYa, Guseva ТN, Garbuzov P.L., Buziashvili I.I., Melnichenko G.A. Long-term results of treatment of toxic goiter with radioactive 131I. Problems of Endocrinology. 2005;51(1):3-9. (In Russ.)] doi: https://doi.org/10.14341/probl20055113-9Esfahani AF, Kakhki VR, Fallahi B, Eftekhari M, Beiki D, Saghari M, Takavar A. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. Hell J. Nucl. Med. 2005;8(3):158–161Esfahani AF, Kakhki VR, Fallahi B, Eftekhari M, Beiki D, Saghari M, Takavar A. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. Hell J. Nucl. Med. 2005;8(3):158–161Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920–80. doi: https://doi.org/10.1210/er.2012-1030Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920–80. doi: https://doi.org/10.1210/er.2012-1030Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B. Effects of antithyroid drugs on radioiodine treatment: systematic review and metaanalysis of randomised controlled trials. BMJ. 2007;334(7592):514. doi: https://doi.org/10.1136/bmj.39114.670150.BEWalter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B. Effects of antithyroid drugs on radioiodine treatment: systematic review and metaanalysis of randomised controlled trials. BMJ. 2007;334(7592):514. doi: https://doi.org/10.1136/bmj.39114.670150.BEBurch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab. 2001;86(7):3016–21. doi: https://doi.org/10.1210/jcem.86.7.7639Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab. 2001;86(7):3016–21. doi: https://doi.org/10.1210/jcem.86.7.7639Bartalena L, Tanda ML, Piantanida E, Lai A. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005;153(1):13–14. doi: https://doi.org/10.1530/eje.1.01938Bartalena L, Tanda ML, Piantanida E, Lai A. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005;153(1):13–14. doi: https://doi.org/10.1530/eje.1.01938Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. J Clin Endocrinol Metab. 2017;1:102(7):2301–2309. doi: https://doi.org/10.1210/jc.2017-00166Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. J Clin Endocrinol Metab. 2017;1:102(7):2301–2309. doi: https://doi.org/10.1210/jc.2017-00166Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of postthyroidectomy hypocalcaemia. Br J Surg. 2014;101(4):307–320. doi: https://doi.org/10.1002/bjs.9384Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of postthyroidectomy hypocalcaemia. Br J Surg. 2014;101(4):307–320. doi: https://doi.org/10.1002/bjs.9384Guo Z, Yu P, Liu Z, Si Y, Jin M: Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol. 2013;79(5):739–746. doi: https://doi.org/10.1111/cen.12209Guo Z, Yu P, Liu Z, Si Y, Jin M: Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol. 2013;79(5):739–746. doi: https://doi.org/10.1111/cen.12209Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 2008;228(3):320–330. doi: https://doi.org/10.1097/00000658-199809000-00005Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 2008;228(3):320–330. doi: https://doi.org/10.1097/00000658-199809000-00005Piantanida E. Preoperative management in patients with Graves' disease. Gland Surg. 2017;6(5):476-481. doi: https://doi.org/10.21037/gs.2017.05.09Piantanida E. Preoperative management in patients with Graves' disease. Gland Surg. 2017;6(5):476-481. doi: https://doi.org/10.21037/gs.2017.05.09Трошина Е.А., Свириденко Н.Ю., Ванушко В.Э., Румянцев П.О., Фадеев В.В., Петунина Н.А. Федеральные клинические рекомендации по диагностике и лечению токсического зоба. // Проблемы Эндокринологии. 2014;60(6):67-77. doi: https://doi.org/10.14341/probl201460667-77Troshina EA, Sviridenko NYu, Vanushko VE, Rumyantsev PO, Fadeev VV, Petunina NA. The federal clinical recommendations on diagnostics and treatment of toxic goiter. Problems of Endocrinology. 2014;60(6):67-77. (In Russ.)] doi: https://doi.org/10.14341/probl201460667-77Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702–755. doi: https://doi.org/10.1210/er.2009-0041Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702–755. doi: https://doi.org/10.1210/er.2009-0041Yoshihara Noh JY, Watanabe Fukushita M, Matsumoto M, Suzuki N, Hoshiyama A, Suzuki A, Mitsumatsu T, Kinoshita A, Kentaro Mikura K, Yoshimura R, Sugino K, Ito K. Exposure to Propylthiouracil in the First Trimester of Pregnancy and Birth Defects: A Study at a Single Institution. J Endocr Soc. 2021;19;5(3):204. doi: https://doi.org/10.1210/jendso/bvaa204Yoshihara Noh JY, Watanabe Fukushita M, Matsumoto M, Suzuki N, Hoshiyama A, Suzuki A, Mitsumatsu T, Kinoshita A, Kentaro Mikura K, Yoshimura R, Sugino K, Ito K. Exposure to Propylthiouracil in the First Trimester of Pregnancy and Birth Defects: A Study at a Single Institution. J Endocr Soc. 2021;19;5(3):204. doi: https://doi.org/10.1210/jendso/bvaa204Эндокринные заболевания и беременность в вопросах и ответах. Руководство для врачей/под ред. И.И. Дедова, Г.А. Мельниченко, Ф.Ф. Бурумкуловой. Москва.: Е-ното, 2024. 336 с.Endokrinnye zabolevaniya i beremennost' v voprosah i otvetah. Rukovodstvo dlya vrachej/pod red. I.I. Dedova, G.A. Mel'nichenko, F.F. Burumkulovoj. Moskva.: E-noto, 2024. 336 s. (In Russ.)]Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238–249. doi: https://doi.org/10.1016/S2213-8587(13)70086-XCooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238–249. doi: https://doi.org/10.1016/S2213-8587(13)70086-XLo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid. 2015;25(6):698–705. doi: https://doi.org/10.1089/thy.2014.0434Lo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid. 2015;25(6):698–705. doi: https://doi.org/10.1089/thy.2014.0434Andersen SL, Olsen J, Carle A, Laurberg P. Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish populationbased study. J Clin Endocrinol Metab. 2015;100(3):1164–1171. doi: https://doi.org/10.1210/jc.2014-3588Andersen SL, Olsen J, Carle A, Laurberg P. Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish populationbased study. J Clin Endocrinol Metab. 2015;100(3):1164–1171. doi: https://doi.org/10.1210/jc.2014-3588Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’disease. Clin Endocrinol. 2016;84(1):115–120. doi: https://doi.org/10.1111/cen.12688Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’disease. Clin Endocrinol. 2016;84(1):115–120. doi: https://doi.org/10.1111/cen.12688Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med. 2017;376(2):184. doi: https://doi.org/10.1056/NEJMc1614624Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med. 2017;376(2):184. doi: https://doi.org/10.1056/NEJMc1614624McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992;2(2):155–159. doi: https://doi.org/10.1089/thy.1992.2.155McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992;2(2):155–159. doi: https://doi.org/10.1089/thy.1992.2.155Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C. Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol. 2014;171(4):451–460. doi: https://doi.org/10.1530/EJE-14-0254Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C. Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol. 2014;171(4):451–460. doi: https://doi.org/10.1530/EJE-14-0254Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’disease. J Clin Endocrinol. Metab. 2007;92:2157–2162Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’disease. J Clin Endocrinol. Metab. 2007;92:2157–2162Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–2403Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–2403Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med. 2018;168(6):405–413. doi: https://doi.org/10.7326/M17-1398Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med. 2018;168(6):405–413. doi: https://doi.org/10.7326/M17-1398Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N , Feng O. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PloS One. 2015;10(5):e0126610. doi: https://doi.org/10.1371/journal.pone.0126610Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N , Feng O. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PloS One. 2015;10(5):e0126610. doi: https://doi.org/10.1371/journal.pone.0126610Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315–389. doi: https://doi.org/10.1089/thy.2016.0457Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315–389. doi: https://doi.org/10.1089/thy.2016.0457Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med. 1981;305(22):1323–1326. doi: https://doi.org/10.1056/NEJM198111263052205Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med. 1981;305(22):1323–1326. doi: https://doi.org/10.1056/NEJM198111263052205Laurberg P/ Remission of Graves’ disease during anti-thyroid drug therapy: time to reconsider the mechanism? Eur J Endocrinol. 2006;155(6):783–786. doi: https://doi.org/10.1530/eje.1.02295Laurberg P/ Remission of Graves’ disease during anti-thyroid drug therapy: time to reconsider the mechanism? Eur J Endocrinol. 2006;155(6):783–786. doi: https://doi.org/10.1530/eje.1.02295Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–78. doi: https://doi.org/10.1056/NEJM199801083380201Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–78. doi: https://doi.org/10.1056/NEJM199801083380201Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733–1738. doi: https://doi.org/10.1056/NEJM199206253262603Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733–1738. doi: https://doi.org/10.1056/NEJM199206253262603Табеева К.И. Клиническое течение эндокринной офтальмопатии после хирургического лечения болезни Грейвса. Дисс. … к-та мед. наук. М.$ 2010. С 51–69.Tabeeva KI. Klinicheskoe techenie endokrinnoj oftal'mopatii posle hirurgicheskogo lecheniya bolezni Grejvsa. Diss. … k-ta med. nauk. M.$ 2010. S 51–69. (In Russ.)]Chen DY., Schneider PF., Zhang XS., Luo XY, He ZM, Chen TH. Changes in graves’ ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves’ disease from 2 prospective, randomized, open-label, blinded end point studies. Exp Clin Endocrinol Diabetes. 2014;122(1):1-6. doi: https://doi.org/10.1055/s-0033-1358484Chen DY., Schneider PF., Zhang XS., Luo XY, He ZM, Chen TH. Changes in graves’ ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves’ disease from 2 prospective, randomized, open-label, blinded end point studies. Exp Clin Endocrinol Diabetes. 2014;122(1):1-6. doi: https://doi.org/10.1055/s-0033-1358484Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. European Group on Graves Orbitopathy: The 2016 European Thyroid Association/ European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26. doi: https://doi.org/10.1159/000443828Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. European Group on Graves Orbitopathy: The 2016 European Thyroid Association/ European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26. doi: https://doi.org/10.1159/000443828Karlsson F, Dahlberg P, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol. 1989;121(2):132–141Karlsson F, Dahlberg P, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol. 1989;121(2):132–141Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrnol Invest. 2015;38:481–487. doi: https://doi.org/10.1007/s40618-015-0257-zBartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrnol Invest. 2015;38:481–487. doi: https://doi.org/10.1007/s40618-015-0257-zLai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L. Lower dose prednisone prevents radioiodineassociated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333–1337. doi: https://doi.org/10.1210/jc.2009-2130Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L. Lower dose prednisone prevents radioiodineassociated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333–1337. doi: https://doi.org/10.1210/jc.2009-2130Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol. 2008;69:943–950. doi: https://doi.org/10.1111/j.1365-2265.2008.03279.xAcharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol. 2008;69:943–950. doi: https://doi.org/10.1111/j.1365-2265.2008.03279.xBartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349–1352. doi: https://doi.org/10.1056/NEJM198911163212001Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349–1352. doi: https://doi.org/10.1056/NEJM198911163212001Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab. 2009;94:3381–3386. doi: https://doi.org/10.1210/jc.2009-0506Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab. 2009;94:3381–3386. doi: https://doi.org/10.1210/jc.2009-0506Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM, EUGOGO. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. doi: https://doi.org/10.1530/EJE-21-0479Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM, EUGOGO. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. doi: https://doi.org/10.1530/EJE-21-0479Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149–163. doi: https://doi.org/10.1159/000438750Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149–163. doi: https://doi.org/10.1159/000438750Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. Thyroid Studies Collaboration: Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–2065. doi: https://doi.org/10.1001/jama.2015.5161Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. Thyroid Studies Collaboration: Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–2065. doi: https://doi.org/10.1001/jama.2015.5161Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S. The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid. 2016;26(6):765–769. doi: https://doi.org/10.1089/thy.2015.0470Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S. The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid. 2016;26(6):765–769. doi: https://doi.org/10.1089/thy.2015.0470Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furukawa Y, Teramukai S, Akamizu T. 2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J. 2016;63:1025–1064. doi: https://doi.org/10.1507/endocrj.EJ16-0336Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furukawa Y, Teramukai S, Akamizu T. 2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J. 2016;63:1025–1064. doi: https://doi.org/10.1507/endocrj.EJ16-0336Burch HB, Wartofsky L. Life-threatening thyrotoxicosis: thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263–277Burch HB, Wartofsky L. Life-threatening thyrotoxicosis: thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263–277Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, et al. Japan Thyroid Association: Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid. 2012;22:661–679. doi: https://doi.org/10.1089/thy.2011.0334Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, et al. Japan Thyroid Association: Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid. 2012;22:661–679. doi: https://doi.org/10.1089/thy.2011.0334Isozaki O, Satoh T, Wakino S, Suzuki A, Iburi T, et al. Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol. 2016;84:912–918. doi: https://doi.org/10.1111/cen.12949Isozaki O, Satoh T, Wakino S, Suzuki A, Iburi T, et al. Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol. 2016;84:912–918. doi: https://doi.org/10.1111/cen.12949Erkan ME, Demirin H, Asik M, Celbek G, Yildirim M, Aydin Y, Gungor A, Dogan AS. Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. Aging Clin Exp Res. 2012;24:714–717. doi: https://doi.org/10.3275/8759Erkan ME, Demirin H, Asik M, Celbek G, Yildirim M, Aydin Y, Gungor A, Dogan AS. Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. Aging Clin Exp Res. 2012;24:714–717. doi: https://doi.org/10.3275/8759Kang AS, Grant CS, Thompson GB, van Heerden JA. 2002 Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery. 2002;132:916–923;discussion 923. doi: https://doi.org/10.1067/msy.2002.128691Kang AS, Grant CS, Thompson GB, van Heerden JA. 2002 Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine. Surgery. 2002;132:916–923;discussion 923. doi: https://doi.org/10.1067/msy.2002.128691Albino CC, Graf H, Sampaio AP, Vigario A, Paz-Filho GJ. Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs. 2008;17:1781–1786. doi: https://doi.org/10.1517/13543780802501325Albino CC, Graf H, Sampaio AP, Vigario A, Paz-Filho GJ. Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs. 2008;17:1781–1786. doi: https://doi.org/10.1517/13543780802501325Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun. 2009;30:169–175. doi: 10.1097/MNM.0b013e3283169148.Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun. 2009;30:169–175. doi: 10.1097/MNM.0b013e3283169148.Camargo R, Corigliano S, Friguglietti C, Gauna A, Harach R, et al. Latin American thyroid society. Latin American thyroid society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol. 2009;53:1167–1175. doi: https://doi.org/10.1590/s0004-27302009000900014Camargo R, Corigliano S, Friguglietti C, Gauna A, Harach R, et al. Latin American thyroid society. Latin American thyroid society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol. 2009;53:1167–1175. doi: https://doi.org/10.1590/s0004-27302009000900014Akbulut A, Aydinbelge FN, Koca G. Radioiodine Treatment for Benign Thyroid Diseases. In (Ed.), Radionuclide Treatments. IntechOpen. 2017. doi: https://doi.org/10.5772/intechopen.68575Akbulut A, Aydinbelge FN, Koca G. Radioiodine Treatment for Benign Thyroid Diseases. In (Ed.), Radionuclide Treatments. IntechOpen. 2017. doi: https://doi.org/10.5772/intechopen.68575Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004;14:933–945. doi: https://doi.org/10.1089/thy.2004.14.933Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004;14:933–945. doi: https://doi.org/10.1089/thy.2004.14.933Wahl RA, Rimpl I, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes. 1998;4:78–84Wahl RA, Rimpl I, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes. 1998;4:78–84Mishra A, Agarwal A, Agarwal G, Mishra SK.Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg. 2001;25:307–310. doi: https://doi.org/10.1007/s002680020100Mishra A, Agarwal A, Agarwal G, Mishra SK.Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg. 2001;25:307–310. doi: https://doi.org/10.1007/s002680020100Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H. Thyroid hormone replacement after thyroid lobectomy. Surgery. 2009;146:554–558;discussion 558–60. doi: https://doi.org/10.1016/j.surg.2009.06.026Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H. Thyroid hormone replacement after thyroid lobectomy. Surgery. 2009;146:554–558;discussion 558–60. doi: https://doi.org/10.1016/j.surg.2009.06.026Di Donna V, Santoro MG, de Waure C, Ricciato MP, Paragliola RM, Pontecorvi A, Corsello SM. 2014 A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid. 2014;24(12):1759-64. doi: https://doi.org/10.1089/thy.2014.0111Di Donna V, Santoro MG, de Waure C, Ricciato MP, Paragliola RM, Pontecorvi A, Corsello SM. 2014 A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid. 2014;24(12):1759-64. doi: https://doi.org/10.1089/thy.2014.0111Matte R, Ste-Marie LG, Comtois R, D'Amour P, Lacroix A, Chartrand R, Poisson R, Bastomsky CH. The pituitary-thyroid axis after hemithyroidectomy in euthyroid man. J Clin Endocrinol Metab. 1981;53:377–380. doi: https://doi.org/10.1210/jcem-53-2-377Matte R, Ste-Marie LG, Comtois R, D'Amour P, Lacroix A, Chartrand R, Poisson R, Bastomsky CH. The pituitary-thyroid axis after hemithyroidectomy in euthyroid man. J Clin Endocrinol Metab. 1981;53:377–380. doi: https://doi.org/10.1210/jcem-53-2-377Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, Dralle H. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg. 2000;24:1335–1341. doi: https://doi.org/10.1007/s002680010221Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, Dralle H. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg. 2000;24:1335–1341. doi: https://doi.org/10.1007/s002680010221Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, Goth M, Dohan O, Kovacs L, Szilagyi G. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes. 1999;107:70–74. doi: https://doi.org/10.1055/s-0029-1212076Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, Goth M, Dohan O, Kovacs L, Szilagyi G. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes. 1999;107:70–74. doi: https://doi.org/10.1055/s-0029-1212076Мельниченко Г.А., Ларина И.И. Синдром тиреотоксикоза. Дифференциальная диагностика и лечение. // Терапевтический архив. — 2018. — Т. 90. — №10. — С.4-13. doi: https://doi.org/10.26442/terarkh201890104-13Mel'nichenko GA, Larina II. Sindrom tireotoksikoza. Differencial'naya diagnostika i lechenie. Terapevticheskij arhiv. 2018; 90(10):4-13.(In Russ.)] doi: https://doi.org/10.26442/terarkh201890104-13

The authors declare that there are no conflicts of interest present.